amlodipine

All published abstracts can be found here 

Abstracts

1. Category 1: Amlodipine Vasoplegia
   • Abstract 1: Vasodilation in patients with calcium channel blocker poisoning treated with high dose insulin: a comparison of amlodipine versus non-dihydropyridines
     • Study of HDI on propranolol poisoned pigs
     • Study of Minnesota HDI protocol
   • Abstract 2: Amlodipine anxiety: a 10-year review of amlodipine associated fatalities
   • Abstract 3: Extracorporeal membrane oxygenation utilization for vasoplegic shock due to pediatric toxic ingestions
     • Data of ECMO in poisoning
2. Category 2: Xylazine
   • Abstract 4: “Tranq dope” opioid overdose: clinical outcomes for emergency department patients with illicit opioid overdose adulterated with xylazine
3. Category 3: Case Reports with Terrifying Clinical Implications
   • Abstract 5: Recovery after poly-drug overdose despite blood flow imaging demonstrating no brain perfusion
   • Abstract 6: Challenges in diagnosing an environmental cause of recurrent methemoglobinemia
   • Abstract 7: Acute thiamine deficiency as a complication of insulin euglycemic therapy for an amlodipine overdose
4. Category 4: Comparative evidence, Prognostication, and Triage
   • Abstract 8: Utility of pre four-hour iron concentration in predicting toxicology
   • Abstract 9: Andexanet alfa vs 4-factor prothrombin complex concentrate for intracranial hemorrhage at a level I trauma hospital
5. Category 5: Rapid Review
   • Abstract 10: Fentanyl and fentanyl analogue exposure among emergency personnel and first responders: a systematic review
   • Abstract 11: Significance of falsely low creatinine values in diagnosing massive acetaminophen ingestion
   • Abstract 12: Large dose intentional ciprofloxacin ingestion associated with false-positive urine immunoassay for oxycodone and fentanyl
   • Abstract 13: Don’t make it a double?: a 20- year review of supratherapeutic amlodipine ingestions while on chronic therapy
   • Abstract 14: Evaluation of pediatric lisdexamfetamine exposures reported to a statewide poison control system
   • Abstract 15: An assessment of the reliability of stated quantity in acute acetaminophen overdoses reported to a regional poison center

Calcium Antagonisten remmen de instroom van Calcium in de cel en verlagen daarmee de spiersamentrekking . Hierdoor neemt de diameter van de vaten toe (ze trekken immers niet meer samen). Er zijn verschillende calciumkanalen, L-type en T-type zijn de belangrijkste, maar er zijn er nog meer, deze vallen buiten het bestek van deze podcast. Calciumantagonisten hebben als bijwerking vochtophoping (oedeem), duizeligheid, hoofdpijn en blozen, maar kunnen ook de spanning van de slokdarmsfincter verlagen, waardoor ze zuurbranden kunnen verergeren.  
Calciumantagonisten zijn effectief als eerstelijns bloeddrukverlager, mogelijk verminderen ze het aantal herseninfarcten en het aantal cardiovasculaire gebeurtenissen. Calciumantagonisten worden ook voor andere aandoeningen dan hoge bloeddruk gebruikt.

Literatuur
1.  Ang HT, Lim KK, Kwan YH, Tan PS, Yap KZ, Banu Z, et al. A Systematic Review and Meta-Analyses of the Association Between Anti-Hypertensive Classes and the Risk of Falls Among Older Adults. Drug Aging. 2018;35(7):625–35.
2.  Katz AM. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol. 1996;28(2):522–9.
3.  Godfraind T. Discovery and Development of Calcium Channel Blockers. Front Pharmacol. 2017;8:286.
4.  Lin Y-C, Lin J-W, Wu M-S, Chen K-C, Peng C-C, Kang Y-N. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. Plos One. 2017;12(12):e0188975.
5.  Wright JM, Musini VM, Gill R. First‐line drugs for hypertension. Cochrane Db Syst Rev. 2018;2018(4):CD001841.
6.  He T, Liu X, Li Y, Liu XY, Wu QY, Liu ML, et al. High-dose calcium channel blocker (CCB) monotherapy vs combination therapy of standard-dose CCBs and angiotensin receptor blockers for hypertension: a meta-analysis. J Hum Hypertens. 2017;31(2):79–88.
7.  Palla M, Ando T, Androulakis E, Telila T, Briasoulis A. Renin‐Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta‐Analysis. J Clin Hypertens. 2017;19(4):344–50.
8.  Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015;67(4):821–70.

Does amlodipine cause ankle or leg swelling? In this episode, I answer this question that was posted in my private FaceBook group. I hope that this brings value to you; if you like this video, let me know in the comments so that I will do more videos like this.

Remember, this is not medical advice, and only your doctor can tell you what you need to do for your high blood pressure. Consult your doctor or health care provider for medical advice.

****
Click here to see how to use a home blood pressure monitor and log.

You can purchase an Omron Blood Pressure Monitor from any big box store or pharmacy. Click here for purchase online.

Visit Hypertension Resistant to Treatment's YouTube Channel for What to Eat?

****

Ask your doctor if you would benefit from vitamins:
Vitamin C with rose hips, Zinc, D3 & K2, Magnesium or this one, B complex, Elderberry, Probiotic  or this one, Melatonin, & Quercetin

****

At Hypertension Resistant to Treatment podcast, website, and YouTube channel, you will get knowledge, training, resources, and support so you can take action to get good blood pressure control. Visit hypertensionresistanttotreatment.com for more detailed information.

#amlodipine #bloodpressure #hypertension

 ****
Hi, I'm Dr. Tonya, a clinical research scientist at the University of Alabama at Birmingham, Alabama, where I hold various positions. I spent the past decade studying hypertension, home blood pressure monitoring and tracking, medication adherence, and readiness and confidence to change lifestyle behaviors.
 
I am an author of six first-authored publications in scientific journals. I have collaborated with colleagues on three published studies with the finding from the landmark study that influenced the new hypertension guidelines released in 2017 (Systolic Blood Pressure Intervention[SPRINT] Trial. You can read my work HERE at this link https://www.ncbi.nlm.nih.gov/pubmed/?term=TONYA+BREAUX-SHROPSHIRE, including my published studies from the landmarked Systolic Blood Pressure Intervention (SPRINT) Trial.
 
I created a blog, podcast, and YouTube channel for you to learn what everybody ought to know about hypertension. Connect with me on Facebook or Twitter.
 
If you liked this podcast, please share it with anyone who could benefit from it.
 
Join me every week for more hypertensionresistattotreatment.com podcast, and hit subscribe to get upcoming episodes immediately when released. 

Voiceover Intro by Mr. Willie Breaux, Jr.
 
Song: My Swag

Disclaimer: This podcast is for educational purposes only and not intended to replace medical advice. I have provided this content based on my clinical and research knowledge. Consult your health care provider for medical advice and treatment and before starting any nutritional supplements or lifestyle practice